A Plasmodium yoelii soluble factor inhibits the phenotypic maturation of dendritic cells by Orengo, Jamie M et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Malaria Journal
Open Access Research
A Plasmodium yoelii soluble factor inhibits the phenotypic 
maturation of dendritic cells
Jamie M Orengo1,2, Kurt A Wong1, Carlos Ocaña-Morgner1,3 and 
Ana Rodriguez*1
Address: 1New York University School of Medicine, Department of Medical Parasitology, 341E. 25th St. New York, NY 10010, USA, 2Regeneron 
Pharmaceuticals, Inc. 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA and 3Institute of Physiological Chemistry, Medical School, MTZ, 
Dresden University of Technology, Fiedlerstr. 42, 01307 Dresden, Germany
Email: Jamie M Orengo - Jamie.Orengo@regeneron.com; Kurt A Wong - kurt.wong@nyumc.org; Carlos Ocaña-Morgner - Carlos.Ocana-
Morgner@mailbox.tu-dresden.de; Ana Rodriguez* - ana.rodriguez@nyu.edu
* Corresponding author    
Abstract
Background: Infection with the protozoan parasite Plasmodium is the cause of malaria. Plasmodium
infects host erythrocytes causing the pathology of the disease. Plasmodium-infected erythrocytes
can modulate the maturation of dendritic cells (DCs) and alter their capacity to activate T cells.
Methods: Mice infected with Plasmodium yoelii and isolated P. yoelii-infected erythrocytes were
used to study their effect on the maturation of mouse dendritic cells.
Results: DCs are not able to mature in response to LPS injection during the late stage of P. yoelii
infection in mice, indicating impaired functionality of these cells in vivo. P. yoelii- infected erythrocytes
inhibit the maturation of DCs in vitro in a dose-dependent manner, which is consistent with the
inhibition found during late infection when parasite burden is highest. The inhibition of DC
maturation and the cytokine secretion profile of DCs are modulated by soluble factors released by
P. yoelii-infected erythrocytes. A small, heat-stable, non-hydrophobic molecule of P. yoelii-infected
erythrocytes rapidly inhibits the LPS induced phenotypic maturation of DCs in a reversible manner.
Conclusion: These findings add evidence to the malaria associated immune suppression in vivo and
in vitro and provide insight into the nature and mechanism of the Plasmodium factor(s) responsible
for altering DC functions.
Background
The interactions of the Plasmodium  parasite with the
immune system of the host are complex in many aspects
regarding the activation and regulation of different types
of immune cells. The specific characteristics of the
immune response may contribute to the successful per-
sistence of the parasite and the slow generation of immu-
nity against the disease that is observed in endemic areas
[1]. Inhibition of specific T cell responses to malaria anti-
gens and T cell depletion have been identified in individ-
uals infected with malaria [2-5]. Immune suppression
does not appear to affect only anti-Plasmodium responses,
but the parasite can also inhibit immune responses to
other organisms. In fact, malaria is associated with a
higher incidence of other infectious diseases [6-8] and
reduced immune responses to vaccinations [9,10]. Studies
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using in vitro P. falciparum cultures or in vivo murine mod-
els with different Plasmodium  strains have shown that
infection is associated with altered macrophage [11-15]
and dendritic cell (DC) responses [16-25]. However,
other studies have found normal DC responses to Plasmo-
dium [26-31].
DCs are antigen presenting cells that play a pivotal role in
the initiation of immune responses, as they form a bridge
between the innate and adaptive immune responses and
possess the unique capacity to initiate primary immune
responses via the activation of naïve T cells [32]. Patho-
gens frequently undermine the immune system by modu-
lating the ability of DCs to initiate an immune response
[33]. The maturation and function of monocyte-derived
human DCs are modulated by P. falciparum-infected
erythrocytes in vitro [16,18,34]. This phenotype is also
supported with field evidence since peripheral blood DCs
from children with acute P. falciparum infection showed
low expression levels of human leukocyte antigen (HLA)-
DR on their surface [35,36], suggesting the functional
impairment of these DCs. Given the crucial role of DCs in
both the innate and adaptive immune responses, modu-
lation of DC functions may provide some explanation as
to why protective immunity to malaria is slow to develop.
Using a murine malaria model, it was tested if parasite
infection affects the capacity of DCs to respond to another
stimulus in vivo and observed that the parasite inhibits the
phenotypic maturation of splenic DCs in response to
lipopolysaccharide (LPS). The P. yoelii inhibition of phe-
notypic DC maturation was dose dependent and contact
independent, which is consistent with previous findings
using the human in vitro model [34]. The culture medium
of P. yoelii-infected erythrocytes inhibits LPS-induced mat-
uration of DCs and performed the biochemical character-
ization of a P. yoelii factor(s) responsible for this activity.
Methods
Reagents, mice and parasites
All chemical reagents were from Sigma unless otherwise
specified. All antibodies for flow cytometry were pur-
chased from BD Biosciences. The parasite used was P. yoe-
lii 17X NL. Female, 6–8 week old Swiss Webster (SW) or
BALB/C mice were purchased from Taconic or the
National institutes of Health (NIH). Monosodium urate
crystals were prepared as previously described [37].
Isolation of CD11c+ DC from P. yoelii-infected mice
For the initiation of parasite infection, mice were injected
intraperatonealy (I.P.) with 106 infected erythrocytes. To
evaluate parasitaemia the number of parasitized erythro-
cytes from 500 cells in a Giemsa-stained thin blood smear
was calculated.
In vivo maturation of CD11c+ cells was induced by intrave-
nous injection (I.V.) of 25 μg/mouse of lipopolysaccha-
ride (LPS) from Salmonella typhimurium diluted in PBS 24
hours before isolation of CD11c+ splenocytes. Control
mice were injected with the same volume of PBS.
Whole spleens were aseptically removed from euthanized
mice and splenocytes were obtained by mechanical dis-
ruption through a cell strainer. Erythrocytes were lysed by
incubation with ammonium chloride/potassium hydro-
gen carbonate buffer (155 mM NH4CL, 1 mM KHCO3, 0.1
mM Na2EDTA) for five minutes followed by washing with
cold DMEM (Mediatech) supplemented with 10% FBS
(Invitrogen Life Technologies) and PSG antibiotic mix
(100 U/ml penicillin, 100 ug/ml streptomycin and 2 mM
L-glutamine; Invitrogen Life Technologies). Cells were
kept on ice at all times. CD11c+ splenocytes were
obtained by positive selection using anti-CD11c antibod-
ies and MACS magnetic columns (Miltenyi Biotec)
according to the manufacturer's instructions. After isola-
tion, cells were washed, stained with the appropriate anti-
bodies, and assayed via flow cytometry for the expression
of co-stimulatory molecules.
Flow cytometry analysis
Prior to staining, DCs were incubated with anti-CD16/
CD32 (FCγIII/II receptor; 2.4 G) for 5 minutes on ice to
prevent the binding of antibodies to Fc receptors. For
analysis, the following antibodies were used: PE anti-
CD11c (HL3), FITC anti-CD40 (3/23) and FITC anti-
CD86 (GL1). All antibodies were used at a 1:100 dilution
in PBS+10% FBS and cells were kept on ice during the
staining procedure. Flow cytometric analysis was per-
formed using a FACSCalibur (BD Biosciences) and Cel-
lQuest (BD Biosciences) or FlowJo (Tree Star) software.
Isolation of erythrocytes from Plasmodium-infected mice
Whole blood was isolated from infected or uninfected
anesthetized SW mice via cardiac puncture and diluted in
100 U heparin/ml PBS. Erythrocytes were washed 3 times
with PBS and separated from plasma and white blood
cells by centrifugation at 1,800 g for 5 minutes. The buffy
coat was removed by pipetting. Erythrocytes were either
used as prepared or further processed depending on the
experiment.
Separation of schizonts from P. yoelii-infected blood
Washed infected erythrocytes were separated into sch-
izont and non-schizont stages by centrifugation using a
53% Accudenz density gradient solution in PBS (Accurate
Chemical and Scientific Corp). Uninfected erythrocytes
from a matched mouse were treated in the same way. The
purified schizonts or uninfected erythrocytes were centri-
fuged at 1,800 g for 5 minutes and washed twice with PBS.Malaria Journal 2008, 7:254 http://www.malariajournal.com/content/7/1/254
Page 3 of 13
(page number not for citation purposes)
This procedure results in preparations with higher than
85% schizonts.
Preparation of the conditioned medium of P. yoelii-
infected erythrocytes
The conditioned medium was prepared as previously
described [38]. Briefly, a culture containing 30% sch-
izonts and 70% of non-schizont stages from a P. yoelii
infected mouse was incubated in DMEM supplemented
with antibiotic mix at a density of 5 × 108/ml for 48 h at
37°C, 5% CO2. Cultures were centrifuges at 1,800 g for 5
minutes to collect the supernatant. This supernatant was
heated to 100°C for 5 minutes, centrifuged at 1,800 g for
5 minutes and filtered through a 0.2 μm diameter filter. A
control conditioned medium was prepared in parallel
using erythrocytes from an uninfected mouse. To mimic
the conditions of schizont lysis in the infected erythro-
cytes preparation, a proportion of erythrocytes was sepa-
rated and lysed by hypo-osmotic treatment with water.
Osmolarity was restored and a culture containing 30%
lysed uninfected erythrocytes and 70% intact uninfected
erythrocytes were incubated in DMEM in the same condi-
tions described for the infected conditioned medium. In
all experiments, 10% FBS was added to the conditioned
medium prior to its addition to DCs.
Incubation of DCs with P. yoelii-infected erythrocytes or 
the conditioned medium of P. yoelii-infected erythrocytes
Murine myeloid bone marrow-derived DCs were differen-
tiated as previously described [38]. Briefly, bone marrow
precursors from femurs and tibias of BALB/c mice were
cultured in Petri dishes for 7–10 days at 37°C, 5% CO2 in
DMEM supplemented with antibiotic mix, 10% FBS, and
30% conditioned medium of the myeloma cell line
Ag8653 that expresses recombinant granulocyte mono-
cyte-colony stimulating factor (GMCSF) [39]. This proce-
dure results in preparations with higher than 90% CD11c+
cells, which also present surface CD40, CD80, CD86 and
MHC-I and II molecules, which are up-regulated in
response to LPS [40].
For experiments involving DC cultured with erythrocytes,
DCs (106/ml) were incubated with uninfected or P. yoelii-
infected erythrocytes at a ratio of 30:1 (iRBC:DC) unless
otherwise indicated. Cells were cultured in DMEM supple-
mented with antibiotic mix, 10% FBS and 5% GM-CSF for
24 hours at 37°C, 5% CO2. DCs were then induced (or
not) to mature with 100 ng/ml LPS and incubated for an
additional 24 hours. Erythrocytes were lysed with ammo-
nium chloride/potassium hydrogen carbonate buffer for 5
minutes. DCs were washed and resuspended in PBS+10%
FBS and stained with the appropriate antibodies for anal-
ysis of co-stimulatory molecules by flow cytometry.
For experiments involving DC cultured with the condi-
tioned medium of P. yoelii-infected erythrocytes, DCs
(106/ml) were incubated with the conditioned medium
for the indicated amount of time and then incubated with
100 ng/ml LPS for an additional 24 h 37°C, 5% CO2. DCs
were harvested, washed, resuspended in PBS+10% FBS,
and stained with the antibodies for analysis of co-stimula-
tory molecules using flow cytometry.
Incubation media from DC-conditioned media co-cul-
tures was collected and assayed by ELISA for the secretion
of IL-6 or IL-12 p70 (OPTI-EIA kit, BD biosciences) or
PGE2 (Cayman Chemicals)
Characterization and molecular identification of P. yoelii 
active molecules
Size fractionation of the conditioned media using Centricon® columns
The conditioned media of uninfected- or P. yoelii-infected
erythrocytes was fractionated using Centricon® (Millipore)
filters of various membrane sizes according the manufac-
turers instructions. Briefly, centrifugal force drives the sep-
aration of solvents and solutes through the membrane
filters of varying sizes into the filtrate vial. The condi-
tioned medium was spun on the Centricon® column at
1,800 g for 90 minutes. The column flow through was col-
lected and used in assays with DCs.
Dialysis of the conditioned medium using Tube-O-Dialyzers
Using Tube-O-Dialyzers (Geno Technology, Inc) with a
molecular weight cut off of 1 kDa, molecules that were
smaller than 1 kDa were dialyzed out of the conditioned
medium of uninfected- or P. yoelii-infected erythrocytes
that were each previously size fractionated to smaller than
3 kDa. Samples were dialyzed against DMEM (1:100
vol:vol) for 8 hours and the DMEM was changed every 2
hours.
Treatment with DNase I
DNase I (EMD Biosciences) was resuspended in DMEM,
without serum, at 10 mg/ml. Endotoxin was removed
from DNase I using the EndoClean kit (BioVintage)
according to the manufacturer's protocol. Then the DNase
I was added to the conditioned media (1 μg/ml) and incu-
bated at 37°C for 2 h. The DNase I was deactivated by
boiling the CM for 10 minutes.
Purification using Sep-Pak® reversed phase columns
The conditioned medium of uninfected- or P. yoelii-
infected erythrocytes was passed through Sep-Pak® reverse
phase columns that retain hydrophobic molecules. The
Sep-Pak® columns were pre-rinsed with 10 mls of 100%
ethanol followed by 10 mls of 0.1% acetic acid. The con-
ditioned media was passed through the column and the
flow through containing non-hydrophobic molecules was
dried and reconstituted in DMEM without salts. The con-
ditioned medium containing hydrobic molecules was
eluted with 70% ethanol, dried, and reconstituted in
DMEM.Malaria Journal 2008, 7:254 http://www.malariajournal.com/content/7/1/254
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Statistical analysis
All data were analysed using GraphPad Prism software.
Significant differences were determined using student's t-
tests or one-way ANOVA. Data were considered signifi-
cant if p < 0.05.
Results
Plasmodium yoelii infection inhibits the in vivo 
maturation of CD11c+ splenocytes
The ability of splenic CD11c+ cells (myeloid DCs) from P.
yoelii-infected Swiss Webster (SW) mice to respond to a
maturation stimulus during late infection in vivo was
tested. The surface expression of the co-stimulatory mole-
cules CD40 and CD86 was measured as an indication of
DC maturation [41]. As reported before for late P. yoelii
infection [17,19,42], the expression of CD40 and CD86
on CD11c+ splenocytes was not significantly upregulated
in response to parasite infection (average parasitaemia,
21.62). When the response to LPS that was injected into
the mice 24 h before was analyzed, CD11c+ splenocytes
from infected mice did not up-regulate the co-stimulatory
molecules CD40 and CD86 (Figure 1). Whereas CD11c+
splenocytes from control uninfected mice increased the
expression of these co-stimulatory molecules in response
to LPS. These results suggest that infection with P. yoelii
inhibits CD11c+ responses to other maturation stimuli,
such as LPS. It is important to note that during late P. yoelii
infection the regulatory DC subset is the dominant DC
population in the spleen, therefore the data presented
here mainly reflect the behavior of this population[42].
In vitro inhibition of DC maturation is dose-dependent
Plasmodium falciparum and P. yoelii-infected erythrocytes
inhibit the LPS induced upregulation of histocompatibil-
ity and co-stimulatory molecules on DCs in vitro [16,17].
Furthermore, it was shown using the human in vitro
model that this inhibition was dose dependent [34]. P.
yoelii-infected erythrocytes, when incubated with murine
myeloid DCs at a ratio of 30:1, were found to inhibit the
LPS induced upregulation of the co-stimulatory molecules
CD40 and CD86 on DC cell surfaces (Figure 2). This fail-
ure to up-regulate co-stimulatory molecules was not
observed when DCs were incubated alone or with unin-
fected RBCs at the same ratio. The inhibitory effect was
dose-dependent and decreased at lower ratios of P. yoelii-
infected erythrocytes to DCs (Figure 2). This is consistent
with observations using the human in vitro model [34];
however, some inhibition of co-stimulatory molecule
expression at lower ratios (10:1 and 1:1 iRBC:DCs) that
was not apparent in the human experiments was still
observed.
Uric acid and the inhibition of DC maturation by P. yoelii-
infected erythrocytes
DCs produce TNF in response to Plasmodium  infected
erythrocytes [29,30,38]. The P. yoelii factor that induces
P. yoelii infection inhibits the in vivo maturation of CD11c+  splenocytes Figure 1
P. yoelii infection inhibits the in vivo maturation of 
CD11c+ splenocytes. SW mice were infected or not with 
106 P. yoelii-infected erythrocytes. At day 10 post infection, 
CD11c+ splenocytes were analysed via flow cytometry for 
their surface expression of co-stimulatory molecules CD40 
and CD86. When indicated, 25 μg/mouse of LPS was injected 
intravenously 24 h prior to spleen harvest. Results are 
expressed as relative fluorescent intensity for the gated 
CD11c+ cells of each mouse compared with the average of 
gated CD11c+ cells from uninfected, unstimulated mice. Each 
symbol is representative of one mouse and each group con-
tains at least 3 mice. Bars represent mean value of each 
group of mice. Differences in surface expression were con-
sidered significant when p < 0.05. * represents significant dif-
ferences in surface expression when compared to LPS 
treated uninfected mice.
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TNF was shown to be Plasmodium-derived hypoxanthine
that is converted into uric acid by xanthine oxidoreduct-
ase present in the serum [38]. Since TNF can induce the
maturation of DCs [43] and it was recently shown that
systemic TNF in Plasmodium-infected mice can impair DC
function [25], it was tested whether hypoxanthine could
also be responsible for the impaired maturation of DCs.
Addition of hypoxanthine to DCs in the presence of
serum results in the secretion of TNF from DCs [38], how-
ever, it did not inhibit the LPS-induced maturation of DCs
(Figure 3A). At high concentrations of hypoxanthine, an
increase in surface co-stimulatory molecules was
observed. This is expected since the products of hypoxan-
thine degradation: reactive oxygen species and uric acid
can both induce DC maturation [37,44]. Despite this
increase in surface markers, DCs were still responsive to
LPS-induced maturation (Figure 3A).
Additionally, it was tested whether the hypoxanthine or
its degradation products accumulated in the conditioned
medium could play a role in the inhibition of DC matura-
tion. Allopurinol is an inhibitor of xanthine oxidoreduct-
ase that blocks hypoxanthine degradation and inhibits P.
yoelii-induced release of TNF by DCs [38]. It was found
that allopurinol did not affect P. yoelii-induced inhibition
of DC maturation (Figure 3B). Therefore, it is unlikely that
hypoxanthine or its degradation pathway are responsible
for the P. yoelii-induced inhibition of DC maturation. On
the contrary, it appears that this pathway may contribute
to the maturation of DCs. It was then tested whether P.
yoelii-infected erythrocytes could also inhibit maturation
induced by uric acid. Uric acid is a danger signal that in
the crystallized form increases the expression of CD86 on
the surface of DCs [37]. Uric acid crystals increased the
surface expression of CD86, but not of CD40. In the pres-
ence of P. yoelii-infected erythrocytes, the uric acid-
induced upregulation of CD86 was not observed (Figure
3C).
Conditioned medium from P. yoelii-infected erythrocytes 
inhibits DC maturation
It has been reported using a transwell culture system that
P. falciparum modulation of DC phenotypic maturation is
not contact dependent [34], suggesting that a soluble fac-
tor(s) is responsible for the effect.
To investigate the possibility that the inhibitory effect
observed is also mediated by a soluble factor, the effects of
a conditioned medium of P. yoelii-infected erythrocytes
(described in methods) was tested on DC responses to
LPS. The conditioned medium of P. yoelii-infected eryth-
rocytes inhibited the LPS induced up-regulation of CD40
and CD86 on the surface of DCs (Figure 4A). A condi-
tioned medium obtained from the incubation of whole
uninfected erythrocytes did not inhibit the maturation of
P. yoelii in vitro inhibition of DC maturation is dose dependent Figure 2
P. yoelii in vitro inhibition of DC maturation is dose 
dependent. DCs were incubated alone (Control), in the 
presence of uninfected RBCs (RBCs) or P. yoelii-infected 
erythrocytes (iRBCs) at the indicated ratio to DCs for 24 h 
followed by an additional 24 h in the presence or absence of 
100 ng/ml LPS. FACS plots show CD40 and CD86 surface 
expression on DCs from control cultures (gray filled histo-
grams) or incubated with LPS (black thick line). Mean fluores-
cent intensity (MFI) values are indicated in each plot for 
control and LPS stimulated. Each FACS plot is representative 
of one of at least 2 independent experiments.
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Uric acid and the inhibition of DC maturation by P. yoelii-infected erythrocytes Figure 3
Uric acid and the inhibition of DC maturation by P. yoelii-infected erythrocytes. (A) DCs were incubated alone 
(Control) or in the presence of various concentrations of hypoxanthine for 24 h followed by an additional 24 h in the absence 
(grey bars) or presence (black bars) of 100 ng/ml LPS. Results are expressed as the relative increase in MFI over DCs incubated 
in media alone. Error bars represent the standard deviation of 3 averaged independent experiments. (B, C) DCs were incu-
bated alone (Control) or with uninfected RBCs (RBCs) or P. yoelii-infected erythrocytes (iRBCs). (B) 2 mM allopurinol was 
added or not to the co-cultures for 24 h followed by an additional 24 h in the presence or absence of 100 ng/ml LPS. (C) Co-
cultures were incubated alone for 24 h before addition of uric acid crystals for additional 24 h. FACS plots show CD40 or 
CD86 surface expression on DCs from control cultures (gray filled histogram) or incubated with LPS (B) or uric acid crystals 
(C) (black thick line). Mean fluorescent intensity (MFI) values are indicated in each plot for control and stimulated. Each FACS 
plot is representative of one of at least 2 independent experiments.
CD40 CD86
21 21
22 24
19 14
46 95
71 113
51 51
Uric Acid
CD40 CD86
123 32
36
38
74 64
89 252 193
102 254 166
+Allopurinol
CD40 CD86
33 213
90 361 32 229
34 69 94 159
84 291
Control
A
R
e
l
a
t
i
v
e
 
i
n
c
r
e
a
s
e
CD86
RBCs
Control
iRBCs
CD40
0
1
2
3
4
5
Control 3 1 0.1 0.01
Hypoxanthine (mM)
0.0
2.5
5.0
7.5
Control 3 1 0.1 0.01
R
e
l
a
t
i
v
e
 
i
n
c
r
e
a
s
e
Hypoxanthine (mM)
BCMalaria Journal 2008, 7:254 http://www.malariajournal.com/content/7/1/254
Page 7 of 13
(page number not for citation purposes)
DCs. However, as a better experimental control, a propor-
tion of the uninfected erythrocytes was lysed to account
for erythrocyte factors that are released as a result of eryth-
rocyte rupture that occurs in the infected erythrocyte prep-
aration. This control conditioned medium did not inhibit
the LPS induced upregulation of CD40 or CD86 on the
surface of DCs (Figure 4A). The inhibitory effect of the
conditioned medium is dose dependent (Figure 4A) and
heat stable, since the inhibitory activity was not affected
after boiling the conditioned medium before incubation
with DCs. These results indicate that a heat-stable soluble
factor(s) derived from P. yoelii-infected erythrocytes inhib-
its the maturation of DCs.
To inhibit DC maturation, P. falciparum and  P. yoelii-
infected erythrocytes are pre-incubated with DCs for 20 to
24 h prior to the addition of a maturation stimulus
[16,17,34]. This suggests that either the factor (s) respon-
sible for inhibiting DC maturation requires time to reach
a threshold concentration in the medium or that the DCs
require time to respond to it. To prepare the P. yoelii-con-
ditioned medium, parasites are incubated in media for 48
h. This is enough time for the inhibitory factor(s) to accu-
mulate in the medium, as evidenced by the inhibitory
response obtained (Figure 4A). This experiment, however,
was performed by pre-incubating the DCs with the condi-
tioned medium for 24 h before adding the maturation
stimulus, as was done with whole infected erythrocytes.
To determine the time of action of the soluble factor(s) on
DC maturation, the conditioned medium of P. yoelii
infected erythrocytes was added to DCs at the same time
as LPS. In these conditions, a strong inhibition of the LPS-
induced maturation was found (Figure 4B), suggesting
that the factor(s) has a rapid effect on DCs.
When DCs were pre-incubated with the conditioned
medium for 24 h, washed and then incubated with DC
medium in the presence or absence of LPS for an addi-
tional 24 h, the inhibitory effect of the conditioned
medium was not observed, as these DCs upregulated
CD40 and CD86 in response to LPS stimulation (Figure
4C). These data suggest that the inhibitory effect of the P.
yoelii factor(s) on DC maturation is reversible. Since the
DCs matured in response to LPS once the conditioned
medium was removed, it also suggests that the P. yoelii-
soluble factor(s) is not toxic to the DCs. It was confirmed
that the conditioned medium of P. yoelii-infected erythro-
cytes did not induce DC death. Using propidium iodide
exclusion to determine the percentage of live DCs, no dif-
ferences were found after incubation for 48 h alone or
with the conditioned medium from infected or unin-
fected erythrocytes.
Conditioned medium modulates DC cytokine production
The effect of the conditioned medium of P. yoelii infected
erythrocytes was tested on the secretion of two inflamma-
tory mediators that are released by DCs in response to P.
yoelii-infected erythrocytes: prostaglandin E2 (PGE2) [45]
and interleukin (IL)-6 [19]. The conditioned medium of
P. yoelii-infected erythrocytes induced DC production of
PGE2 (Figure 5A) and IL-6 (Figure 5B), whereas the condi-
tioned medium of uninfected erythrocytes did not induce
the production of these inflammatory mediators. The con-
ditioned medium of P. yoelii-infected erythrocytes also
induces the secretion of TNF from DCs [38].
Pre-incubation of DCs with P. yoelii- or P. falciparum-
infected erythrocytes does not induce IL-12 production,
but instead inhibits the secretion of IL-12 in response to
LPS [17,18,34]. The incubation of DCs with the condi-
tioned medium of P. yoelii infected erythrocytes also
resulted in a failure of these cells to secrete IL-12 in
response to stimulation with LPS (Figure 5C). Moreover,
this was a rapid inhibition, as the conditioned medium
was added concurrently with LPS.
Characterization of the P. yoelii soluble factor(s) that 
inhibits DC maturation
To further characterize the P. yoelii factor(s) that inhibits
DC maturation, the conditioned medium was fraction-
ated by size using Centricon® filters of various membrane
pore sizes prior to incubation with DCs. When the P. yoe-
lii-conditioned medium was size fractionated to smaller
than 30 kDa, 10 kDa or 3 kDa there was inhibition of the
LPS-induced up-regulation of CD40 and CD86 (Figure
6A). No inhibitory activity was found in the high molecu-
lar weight (>30 kDa, 10 kDa or 3 kDa) fractions.
Molecules smaller than 1 kDa were dialyzed out from the
P. yoelii-conditioned medium that was previously size
fractionated to smaller than 3 kDa using Tube-O-Dialyz-
ers® dialysis tubes. When this fractionated, dialyzed condi-
tioned medium was incubated with DCs, the inhibitory
effect was lost and the DCs up-regulated surface expres-
sion of CD40 and CD86 in response to LPS stimulation
(Figure 6B), indicating that the inhibitory molecule(s)
was smaller than 1 kDa. The inhibitory activity was also
found not to be sensitive to extensive treatment with
DNase I.
The non-hydrophobic fraction of the conditioned
medium of P. yoelii-infected erythrocytes retained the abil-
ity to inhibit the LPS induced upregulation of CD40 and
CD86 on the surface of DCs (Figure 6C). Conversely, the
conditioned medium containing the hydrophobic mole-
cules did not inhibit the LPS induced upregulation of
CD40 and CD86 to the DC surface (Figure 6C).
These data suggest that a small, soluble, non-hydrophobic
molecule of P. yoelii infected erythrocytes inhibits the LPS
induced phenotypic maturation of DCs.Malaria Journal 2008, 7:254 http://www.malariajournal.com/content/7/1/254
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Discussion
A number of studies have analysed the response of DCs
incubated with human or mouse Plasmodium-infected
erythrocytes in vitro or obtained from Plasmodium-infected
mice ex vivo. Some of these studies found a normal DC
maturation response [26-31,46], but others have found
inhibition of DC maturation [16-21,23,25]. This apparent
controversy has been resolved recently since it was found
that the behavior of DCs is dependent on the strain of
infecting parasite [24] and the subpopulation of DC ana-
lysed [42]. Additionally, the initial dose of parasite inocu-
lated to induce infection and the time when DCs are
analysed during infection influences the maturation state
of DCs [42].
In this study, the DC response to a maturation stimulus in
vivo in infected mice during late P. yoelii infection was
analised. In these conditions, splenic DCs are found in an
The conditioned medium of P. yoelii-infected erythrocytes inhibits DC maturation Figure 4
The conditioned medium of P. yoelii-infected erythrocytes inhibits DC maturation. (A) DCs were incubated alone 
(Control), in the presence of the conditioned media of uninfected (CM-RBCs) or P. yoelii-infected (CM-iRBCs) erythrocytes for 
24 h followed by an additional 24 h in the absence (grey bars) or presence (black bars) of 100 ng/ml LPS. The CM-iRBCs was 
diluted 50% in medium or not (100%). Results are expressed as the relative increase in MFI over DCs incubated in media alone. 
Error bars represent the standard deviation of 3 averaged independent experiments. *, indicates significant differences in DC 
surface expression when compared to DC incubated with CM-RBCs and stimulated with LPS. (B) DCs were incubated with 
either the conditioned medium of uninfected (CM-RBCs) or P. yoelii-infected (CM-iRBCs) erythrocytes in the presence or 
absence of 100 ng/ml LPS for 24 h. (C) DCs were incubated in the presence of the conditioned medium of uninfected (CM-
RBCs) or P. yoelii-infected (CM-iRBCs) erythrocytes for 24 h. DCs were washed and incubated in media alone for 24 h in the 
presence or absence of 100 ng/ml LPS. (B, C) FACS plots show CD40 or CD86 surface expression on DCs from control cul-
tures (gray filled histogram) or incubated with LPS (black thick line). Mean fluorescent intensity (MFI) values are indicated in 
each plot for control and LPS stimulated. Each FACS plot is representative of one of at least 2 independent experiments.
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immature state and do not respond to LPS injection. It has
been shown that DCs become refractory to TLR-mediated
secretion of IL-12 and TNF during late P. yoelii infection
[46]. This study also indicates that DCs are refractory to
LPS stimulation. Since the DCs are found in an immature
state, it suggests that there is a parasite-induced active
inhibition rather than a tolerogenic effect caused by previ-
ous P. yoelii DC activation.
Recently we showed that Plasmodium-derived uric acid
induces DC production of TNF [38]. Uric acid crystals
have been identified as a danger signal that induces DC
maturation [37]. It was found that in the presence of P.
yoelii  infected erythrocytes, DCs do not phenotypically
mature in response to uric acid, which further broadens
malaria induced suppression implications.
The inhibition of LPS-induced DC maturation was
dependent on the dose of P. yoelii infected erythrocytes.
This is consistent with findings observed using human
DCs and P. falciparum [34] and suggests that this inhibi-
tory effect would be most relevant during late infection
when parasite loads are higher.
Using conditioned medium of P. yoelii-infected erythro-
cytes, it was determined that the P. yoelii-infected erythro-
cyte factor(s) that inhibits the LPS-induced phenotypic
maturation of DCs was soluble. Upon further characteri-
zation, this factor was found to be heat stable, smaller
than 1 kDa and non-hydrophobic. It is possible that this
factor is produced by the parasite itself, or alternatively,
Plasmodium could induce its production by host erythro-
cytes upon infection. It is not clear whether this factor
would perform the same activity during infection in vivo
since it requires a high concentration of infected erythro-
cytes to reach activity in vitro. However, infected erythro-
cytes accumulate in certain organs during infection [47],
where local concentrations of the inhibitory factor may be
reached.
It has been proposed that the inhibition of DC maturation
is mediated by the binding of the P. falciparum protein
PfEMP1, which is expressed on the surface of infected
erythrocytes [48], to CD36 on the surface of DCs [16].
This was based on the observation that a non-adherent
parasite cell line, which does not express PfEMP1, does
not inhibit the maturation of DCs [16]. In addition, the
authors observed that antibodies to CD36 inhibited mat-
uration of DCs in a similar manner to P. falciparum-
infected erythrocytes [35]. Conversely, it has been
reported that P. falciparum modulation of DC phenotypic
maturation is not contact dependent and does not
required binding of CD36 and PfEMP1[34], suggesting
that a soluble factor(s) is responsible for the effect. Since
only a small subset of murine DCs express CD36 [49,50]
and P. yoelii does not have genes homologous to PfEMP1
The conditioned medium of P. yoelii-infected erythrocytes modulates DC cytokine production Figure 5
The conditioned medium of P. yoelii-infected erythrocytes modulates DC cytokine production. (A-C) DCs were 
incubated with medium alone (control), the conditioned medium of uninfected (CM-RBCs) or P. yoelii-infected (CM-iRBCs) 
erythrocytes for 24 h in the absence (grey bars) or presence (black bars) of 100 ng/ml LPS. (A) PGE2, (B) IL-6 or (C) IL-12 p70 
concentrations were determined in the incubation medium by ELISA. Error bars represent the standard deviation of 3 aver-
aged independent experiments. *, represents significant differences in IL-6 or PGE2 production by DCs in the presence of CM-
iRBCs when compared to production in the presence of CM-RBCs. **, represents significant differences in IL-12 production by 
DCs in the presence of CM-iRBCs with LPS when compared to production in the presence of CM-RBCs with LPS.
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Characterization of the P. yoelii soluble factor that inhibits DC maturation Figure 6
Characterization of the P. yoelii soluble factor that inhibits DC maturation. (A-C) DCs were incubated alone (Con-
trol), in the presence of the conditioned media of uninfected (CM-RBCs) or P. yoelii-infected (CM-iRBCs) erythrocytes for 24 h 
followed by an additional 24 h in the absence (grey bars) or presence (black bars) of 100 ng/ml LPS. (A) Prior to incubation 
with DCs, conditioned medium of P. yoelii-infected erythrocytes (CM-iRBCs) was size fractioned using Centricon® filters to 
smaller than 30 kDa (<30), 10 kDa (<10) and smaller than 3 kDa (<3). (B) Prior to incubation with DCs, molecules of smaller 
than 1 kDa were dialyzed out of the P. yoelii conditioned medium that was previously size fractioned to smaller than 3 kDa 
(3>CM>1). (C) Prior to incubation with DCs, The conditioned medium was fractionated based on hydrophobicity using Sep-
Pak® columns. (A-C) Results are expressed as the relative increase in MFI over DCs incubated in media alone. Error bars rep-
resent the standard deviation of 3 averaged independent experiments. *, represents significant differences in DC surface 
expression when compared to surface expression on DCs incubated with CM-RBCs and matured with LPS. **, represents sig-
nificant differences in DC surface expression when compared to surface expression on DCs incubated with CM-iRBCs and 
matured with LPS.
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[51], the modulation of DCs by a soluble factor(s) derived
from P. yoelii-infected erythrocytes is likely homologous
to the later mechanism [34].
An immune suppressive role for hemozoin has been pro-
posed [52,53], including an inhibitory effect on DC mat-
uration [20,23,54]. However, other reports propose
hemozoin as an immune activator because of its ability as
a purified extract to enhance DC maturation [55,56].
Recently, it was shown that parasite DNA that is associ-
ated with hemozoin after release from ruptured infected
erythrocytes is responsible for the activation of DCs [57].
Haemozoin is not likely to be responsible for the DC inhi-
bition observed in this work, since the size fractionation
experiments showed that the inhibitory activity is smaller
than 1 kDa and the hemozoin pigment has a much higher
molecular weight. No inhibitory activity on DCs of the
fractions higher than 30 kDa was found. Additionally, it
was also shown that the inhibitory activity of the condi-
tioned medium is not sensitive to DNase I treatment,
excluding parasite DNA as a mediator of the DCs inhibi-
tory activity.
DCs possess the capacity to secrete immune regulatory
cytokines, such as IL-12, which is an important cytokine
involved in the initiation of cellular immune responses
[58]. It was observed that a soluble factor(s) of P. yoelii-
infected erythrocytes inhibits the LPS-induced production
of IL-12 by DCs. It is not clear yet whether the same para-
site-derived factor(s) is responsible for the inhibition of
maturation and IL-12 secretion or these two effects are
caused by different factors. Regardless, they both probably
contribute to impaired T cell responses in the host, since
the activation of Th1 cells requires both up-regulation of
co-stimulatory molecules on DCs and secretion of IL-12
[58].
Despite parasite inhibition of DC phenotypic maturation,
DCs still produce TNF, IL-6 and PGE2 in response to Plas-
modium infected erythrocytes [18,19,38,45]. The P. yoelii
factor that induces TNF, and at least part of the PGE2 and
IL-6, was shown to be Plasmodium-derived hypoxanthine
that is converted into uric acid [38]. Since TNF can induce
the maturation of DCs and it was recently shown that sys-
temic TNF in Plasmodium-infected mice can impair the DC
function [25], it was tested whether hypoxanthine in the
conditioned medium or uric acid produced after its degra-
dation were responsible for the impaired maturation of
DCs observed.
It was confirmed that Plasmodium-derived hypoxanthine
degradation into uric acid is not responsible for the inhi-
bition of maturation observed in this study. However, it is
remarkable that Plasmodium appears to use another small,
non-hydrophobic molecule(s) to modulate host DC
responses.
Additionally, the P. yoelii conditioned medium induces
PGE2 and IL-6 secretion from DCs, which are important
immune mediators during Plasmodium  infection. PGE2
produced during blood stage P. yoelii infection has a gen-
eral T cell inhibitory activity and in particular inhibits pro-
tective CD8+ T cell responses against the liver stage [45].
While a specific role of DC IL-6 production during malaria
is unknown, IL-6 is considered an important regulator of
the transition from the innate to acquired immune
responses and it may also influence DC maturation via
the inhibition of nuclear factor kappa B (NFκB) [59]. It
was shown that P. yoelii triggers the early secretion of PGE2
in DCs, which in turn induces the secretion of IL-6 later in
these cells [19]. Secretion of IL-6 by DCs is in part caused
by parasite-derived uric acid, but is in part independent of
this pathway [38]. Therefore, the same parasite-derived
factor(s) that is responsible for the inhibition of matura-
tion could also contribute to uric acid independent IL-6
secretion.
DCs play a pivotal role in the immune response to patho-
gens. Using the human malaria parasite P. falciparum,
human DCs were observed to be modulated [16,18,34].
These findings were supported by field studies in children
that showed a decrease in HLA-DR expression on periph-
eral DCs from children with acute P. falciparum malaria
[35,36]. Furthermore, it was shown that severe P. falci-
parum infection increases the frequency of BDCA3+ mye-
loid DCs in the peripheral circulation was increased and
the expression of HLA-DR was decreased when comparing
children with acute malaria to healthy controls [36].
The findings presented in this study are consistent with
those observed in the children with acute P. falciparum
infection [35,36], with those observed using a human in
vitro  model [16,18,34], and with those observed for
murine late infections [17,19,20,42,45,46]. This study
indicates that P. yoelii-infected erythrocytes inhibit the
maturation of DCs at high densities and produce a soluble
factor(s) responsible for this effect. During Plasmodium
infection DCs receive stimulatory signals provided by par-
asite-derived molecules such as GPI [60], hemozoin-asso-
ciated parasite DNA [57], elevated concentrations of
Plasmodium-derived uric acid [38] and probably other
molecules that have not been yet characterized. At the
same time the parasite appears to release a soluble fac-
tor(s) that interferes with the maturation of DCs. It is pos-
sible that the balance between these effects is switched
during the progression of infection, such that the inhibi-
tory effect may be more active during late infection when
parasite loads are higher.Malaria Journal 2008, 7:254 http://www.malariajournal.com/content/7/1/254
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Conclusion
It was observed that P. yoelii infection interferes with the
maturation of DCs both in vivo and in vitro. During late
infection,  P. yoelii inhibits the maturation of murine
splenic DCs. In vitro, P. yoelii-infected erythrocytes inhibit
the maturation of DCs in a dose-dependent manner and
also modify their cytokine secretion pattern. A small, heat-
stable, non-hydrophobic molecule derived from P. yoelii-
infected erythrocytes is responsible for the inhibition of
DC maturation.
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